HRP20010473A2 - Combination chemotherapy - Google Patents

Combination chemotherapy Download PDF

Info

Publication number
HRP20010473A2
HRP20010473A2 HR20010473A HRP20010473A HRP20010473A2 HR P20010473 A2 HRP20010473 A2 HR P20010473A2 HR 20010473 A HR20010473 A HR 20010473A HR P20010473 A HRP20010473 A HR P20010473A HR P20010473 A2 HRP20010473 A2 HR P20010473A2
Authority
HR
Croatia
Prior art keywords
methyl
phenylamino
iodo
benzamide
difluoro
Prior art date
Application number
HR20010473A
Other languages
English (en)
Croatian (hr)
Inventor
Richard Carelton Gowan
Judith Sebolt-Leopold
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HRP20010473A2 publication Critical patent/HRP20010473A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20010473A 1998-12-22 2001-06-21 Combination chemotherapy HRP20010473A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11329198P 1998-12-22 1998-12-22
US16478899P 1999-11-10 1999-11-10
PCT/US1999/030485 WO2000037141A1 (en) 1998-12-22 1999-12-21 Combination chemotherapy

Publications (1)

Publication Number Publication Date
HRP20010473A2 true HRP20010473A2 (en) 2002-08-31

Family

ID=26810891

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010473A HRP20010473A2 (en) 1998-12-22 2001-06-21 Combination chemotherapy

Country Status (31)

Country Link
EP (1) EP1140291B1 (xx)
JP (1) JP2002532570A (xx)
KR (1) KR20010099877A (xx)
CN (1) CN1333698A (xx)
AP (1) AP2001002175A0 (xx)
AT (1) ATE310567T1 (xx)
AU (1) AU2203900A (xx)
BG (1) BG105715A (xx)
BR (1) BR9916839A (xx)
CA (1) CA2352326A1 (xx)
CZ (1) CZ20012139A3 (xx)
DE (1) DE69928568T2 (xx)
EA (1) EA200100687A1 (xx)
EE (1) EE200100339A (xx)
ES (1) ES2253928T3 (xx)
GE (1) GEP20043172B (xx)
HK (1) HK1042057A1 (xx)
HR (1) HRP20010473A2 (xx)
HU (1) HUP0104844A3 (xx)
ID (1) ID30250A (xx)
IL (1) IL143939A0 (xx)
IS (1) IS5969A (xx)
MA (1) MA26768A1 (xx)
NO (1) NO20013099L (xx)
NZ (1) NZ512859A (xx)
OA (1) OA11733A (xx)
PL (1) PL348326A1 (xx)
SK (1) SK8712001A3 (xx)
TR (1) TR200101871T2 (xx)
WO (1) WO2000037141A1 (xx)
YU (1) YU45401A (xx)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960614B2 (en) 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
CA2419567A1 (en) 2000-09-01 2002-03-07 George Vande Woude Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
EP1377312A4 (en) * 2001-03-22 2004-10-06 Andel Inst Van ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
WO2005035493A1 (ja) * 2003-10-08 2005-04-21 Teijin Pharma Limited アミノピロリジン誘導体の製造方法および中間体化合物
RU2352558C2 (ru) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Полиморфная форма n-[(r)-2,3-дигидроксипропокси]-3,4-дифтор-2-(2-фтор-4 йодфениламино)бензамида
EA013212B1 (ru) 2004-10-20 2010-04-30 Лаборатуар Сероно Са 3-ариламинопиридиновые производные
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
CA2927656C (en) 2005-10-07 2019-09-24 Exelixis, Inc. Mek inhibitors and methods of their use
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
AU2006313701B2 (en) 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
CA2671982C (en) 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
CN103038364A (zh) 2010-03-09 2013-04-10 达纳-法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
CN103301096B (zh) * 2012-03-14 2015-05-06 中国中化股份有限公司 取代二苯胺类化合物作为制备抗肿瘤药物的应用
MX2015004660A (es) 2012-10-12 2015-08-07 Exelixis Inc Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer.
JP6465790B2 (ja) * 2013-02-27 2019-02-06 第一三共株式会社 Mapkシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1997032604A1 (en) * 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
JP2001517954A (ja) * 1997-03-21 2001-10-09 ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム Noey2遺伝子組成物およびその使用方法
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP3028699A1 (en) 2010-02-25 2016-06-08 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
ES2253928T3 (es) 2006-06-01
EP1140291B1 (en) 2005-11-23
HUP0104844A3 (en) 2003-05-28
NZ512859A (en) 2004-06-25
CA2352326A1 (en) 2000-06-29
IS5969A (is) 2001-06-14
SK8712001A3 (en) 2002-02-05
ATE310567T1 (de) 2005-12-15
EP1140291A1 (en) 2001-10-10
YU45401A (sh) 2004-07-15
NO20013099L (no) 2001-08-20
WO2000037141A9 (en) 2000-12-07
KR20010099877A (ko) 2001-11-09
DE69928568T2 (de) 2006-07-27
IL143939A0 (en) 2002-04-21
EA200100687A1 (ru) 2001-12-24
OA11733A (en) 2005-05-12
TR200101871T2 (tr) 2001-10-22
GEP20043172B (en) 2004-02-25
HUP0104844A2 (en) 2002-06-29
AU2203900A (en) 2000-07-12
AP2001002175A0 (en) 2001-06-21
CN1333698A (zh) 2002-01-30
JP2002532570A (ja) 2002-10-02
DE69928568D1 (de) 2005-12-29
HK1042057A1 (zh) 2002-08-02
BG105715A (en) 2002-04-30
MA26768A1 (fr) 2004-12-20
CZ20012139A3 (cs) 2002-01-16
WO2000037141A1 (en) 2000-06-29
NO20013099D0 (no) 2001-06-21
PL348326A1 (en) 2002-05-20
BR9916839A (pt) 2001-10-09
ID30250A (id) 2001-11-15
EE200100339A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
HRP20010473A2 (en) Combination chemotherapy
AU776788C (en) Treatment of arthritis with MEK inhibitors
US6251943B1 (en) Method of treating or preventing septic shock by administering a MEK inhibitor
EP0993437B1 (en) 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
EP1140062B1 (en) Treatment of asthma with mek inhibitors
WO2000040237A1 (en) Antiviral method using mek inhibitors
EP1140046A1 (en) Use of a mek inhibitor for preventing transplant rejection
US20040171632A1 (en) Combination chemotherapy
US20140128398A1 (en) Compounds, compositions and methods for treating oxidative dna damage disorders
PIĄTKOWSKA-CHMIEL et al. THE ANALGESIC EFFECT OF 1, 3-THIAZOLIDIN-4-ONE DERIVATIVES AS POTENTIAL MODULATORS OF THE SEROTONINERGIC SYSTEM.
MXPA01005476A (en) Combination chemotherapy
JP2007519698A (ja) 中枢神経系の疾患および障害の治療および予防用の医薬処方を製造するためのベンゾナフトアズレン類の使用

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn